🏛️ Verified NIH Record • Updated 2026-07-02
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT06143878)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Who can join: Review the eligibility criteria below.
Location: Medical Dermatology Specialists — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (164 Sites)
Showing the first 25 of 164 sites.
- Medical Dermatology Specialists — Phoenix, Arizona
- Center for Dermatology and Plastic Surgery — Scottsdale, Arizona
- Johnson Dermatology — Fort Smith, Arkansas
- First OC Dermatology — Fountain Valley, California
- Center for Dermatology Clinical Research — Fremont, California
- Integrative Skin Science and Research — Sacramento, California
- Southern California Dermatology — Santa Ana, California
- Clinical Science Institute — Santa Monica, California
- Driven Research LLC — Miami, Florida
- Ziaderm Research LLC — North Miami Beach, Florida
- Renstar Medical Research — Ocala, Florida
- Forcare Clinical Research Inc — Tampa, Florida
- Hamilton Research LLC — Alpharetta, Georgia
- Skin Care Physicians of Georgia — Macon, Georgia
- DeNova Research — Chicago, Illinois
- Arlington Dermatology — Rolling Meadows, Illinois
- Endeavor Health — Skokie, Illinois
- Dundee Dermatology — West Dundee, Illinois
- Dawes Fretzin Clinical Research Group LLC — Indianapolis, Indiana
- Indiana Clinical Trial Center — Plainfield, Indiana
- Dermatology Specialists — Louisville, Kentucky
- Dermatology and Advanced Aesthetics — Lake Charles, Louisiana
- Tufts Medical Center — Boston, Massachusetts
- David Fivenson MD, Dermatology — Ann Arbor, Michigan
- Michigan Center of Medical Research — Clarkston, Michigan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.